Current Molecular Pharmacology (CMP), a peer-reviewed international journal dedicated to publishing cutting-edge advances in cellular and molecular pharmacology, is proud to announce a major achievement: its 2025 real-time CiteScore has advanced to an outstanding 7.2. This milestone reflects the journal's growing impact and commitment to excellence in the field.
CMP focuses on critical areas of modern pharmacology, including the mechanisms of action of novel drugs, advancements in pharmacological technologies (such as high-throughput screening, AI-driven drug discovery, and nanotechnology), and the application of genomics, proteomics, and metabolomics in understanding drug effects. With a 2024 Impact Factor of 2.9 and stable rankings in Q2 (Pharmacology & Pharmacy) and Q3 (Biochemistry & Molecular Biology), CMP continues to strengthen its position as a key platform for high-quality research.
The journal’s comprehensive scope encompasses drug-receptor interactions, cell signaling pathways, translational studies linking molecular pharmacology to clinical outcomes, and innovative experimental models. As an open-access publication, CMP ensures global accessibility and visibility, being indexed in prestigious databases such as SCIE, PubMed/MEDLINE, Scopus, and EMBASE.
The achievement of a 7.2 CiteScore reflects the journal’s rigorous peer-review process, the quality of published work, and its relevance to the scientific community. CMP remains committed to fostering innovation and collaboration in pharmacology and looks forward to continuing its trajectory of growth and excellence.